CN108938785B - Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof Download PDFInfo
- Publication number
- CN108938785B CN108938785B CN201710350423.XA CN201710350423A CN108938785B CN 108938785 B CN108938785 B CN 108938785B CN 201710350423 A CN201710350423 A CN 201710350423A CN 108938785 B CN108938785 B CN 108938785B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- traditional chinese
- herb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 208000006673 asthma Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 201000004897 cough variant asthma Diseases 0.000 title claims abstract description 16
- 241000218671 Ephedra Species 0.000 claims abstract description 22
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 22
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 22
- 241000471262 Ardisia japonica Species 0.000 claims abstract description 21
- 241000132446 Inula Species 0.000 claims abstract description 21
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 21
- 235000011477 liquorice Nutrition 0.000 claims abstract description 21
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 7
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 7
- 241001662414 Aster tataricus Species 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 229940079593 drug Drugs 0.000 claims description 27
- 239000000843 powder Substances 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 244000144725 Amygdalus communis Species 0.000 claims description 15
- 241000132092 Aster Species 0.000 claims description 14
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 241000243684 Lumbricus Species 0.000 claims description 3
- 239000000287 crude extract Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000007670 refining Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims 1
- 238000001256 steam distillation Methods 0.000 claims 1
- 238000003809 water extraction Methods 0.000 claims 1
- 206010011224 Cough Diseases 0.000 description 36
- 230000000694 effects Effects 0.000 description 24
- 210000004072 lung Anatomy 0.000 description 21
- 206010062717 Increased upper airway secretion Diseases 0.000 description 16
- 208000026435 phlegm Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108010058846 Ovalbumin Proteins 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000013116 chronic cough Diseases 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- -1 Gum Acacia Chemical compound 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000000210 effect on cough Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating cough variant asthma and a preparation method thereof. The traditional Chinese medicine composition is prepared from radix sophorae flavescentis, fried ephedra herb, bitter apricot seed, Japanese ardisia herb, earthworm, dried orange peel, inula flower, radix peucedani, fried tatarian aster root and liquorice according to a certain weight ratio. It is prepared into an oral preparation, and the traditional Chinese medicine composition has the function of treating cough variant asthma.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition for treating cough variant asthma and a preparation method thereof, belonging to the technical field of traditional Chinese medicines.
Background
Cough Variant Asthma (CVA), also known as occult asthma or cough-type asthma, is a particular type of asthma. It is characterized by that it has no any wheeze or dyspnea symptom, so that it is often missed to diagnose and mistreated, and the disease condition is prolonged and worsened. At the beginning of the attack of bronchial asthma, about 5% to 6% of bronchial asthma is mainly manifested by persistent cough, which often occurs at night or in the early morning, often as irritant cough, and at this time, it is often misdiagnosed as bronchitis. In recent years, the problem has attracted the attention of many scholars at home and abroad, and the asthma accounts for 24 percent and is in the 2 nd place among the single causes of chronic cough, and 28 percent of asthma patients have cough as the only clinical symptom.
At present, bronchodilators, inhaled glucocorticoids and leukotriene receptor antagonists are used as main treatment medicines in western medicine for treating cough variant asthma, cough symptoms can be controlled in a short time, and the like, but adverse reactions, many complications, high recurrence rate and the like exist in long-term treatment.
The invention applies the Chinese medicine theory, adopts the Chinese medicine prescription to treat cough variant asthma, has unexpected effect, and has small side effect, lasting effect and difficult relapse.
Disclosure of Invention
The invention aims to provide a novel traditional Chinese medicine composition which has the effects of dispelling wind and relieving spasm, relieving cough and calming asthma, and is used for treating cough variant asthma wind evil lingering lung, symptoms of irritative dry cough or choking cough, cough caused by throat itching, chest distress and shortness of breath during cough, exacerbation at night or in the early morning, no phlegm or a small amount of mucus phlegm, dry mouth, nasal obstruction and running nose, aversion to wind and other symptoms, reddish tongue, white fur and floating pulse.
It is another object of the present invention to provide a process for the preparation of the above composition.
The invention is realized by the following technical scheme:
the traditional Chinese medicine composition for treating cough variant asthma provided by the invention is prepared from the following traditional Chinese medicine raw materials: radix Sophorae Flavescentis, herba Ephedrae preparata, semen Armeniacae amarum, herba Ardisiae Japonicae, Lumbricus, pericarpium Citri Tangerinae, Inulae flos, radix Peucedani, radix Asteris preparata, and Glycyrrhrizae radix.
The traditional Chinese medicine composition for treating cough variant asthma is prepared from the following raw materials in parts by weight: 1-15 parts of radix sophorae flavescentis, 1-15 parts of roasted ephedra herb, 1-15 parts of bitter almond, 3-20 parts of Japanese ardisia herb, 3-20 parts of earthworm, 1-15 parts of dried orange peel, 1-15 parts of inula flower, 3-20 parts of radix peucedani, 3-20 parts of roasted aster and 1-15 parts of liquorice.
Preferably 2-10 parts of radix sophorae flavescentis, 2-10 parts of fried ephedra, 2-10 parts of bitter almond, 5-15 parts of Japanese ardisia, 5-15 parts of earthworm, 2-10 parts of dried orange peel, 2-10 parts of inula flower, 5-15 parts of radix peucedani, 5-15 parts of fried aster and 2-10 parts of liquorice.
More preferably: 5 parts of radix sophorae flavescentis, 6 parts of roasted ephedra herb, 6 parts of bitter almond, 10 parts of Japanese ardisia herb, 10 parts of earthworm, 6 parts of dried orange peel, 6 parts of inula flower, 10 parts of radix peucedani, 10 parts of roasted aster and 5 parts of liquorice.
The raw material medicaments can be any crude drug or combination of any processed product. The preparation prepared from the raw material medicines in parts by weight is taken in 3 times a day.
The invention is based on the theory of traditional Chinese medicine, adopts the formula of the effective medicines which are matched with each other, and achieves the effects of dispelling wind and relieving spasm, and relieving cough and asthma. Can be used as an effective formulation for cough variant asthma. Wherein,
flavescent sophora root: bitter in taste and cold in nature, it enters lung meridian. Has the functions of clearing away heat, dispersing lung qi, relieving cough and asthma. In Nei Jing, the interior syndrome of the cloud indicates that the lung has bitter flavor and adverse rising of qi, and the lung takes bitter flavor to purge. The sophora flavescens can dispel wind and relieve itching, has the function of clearing wind evil of long-term tiny collaterals, and can relieve itching and asthma when wind goes away. Modern pharmacological research shows that the kuh-seng is a powerful anti-inflammatory drug with hormone-like effect and no hormone-like side effect, and simultaneously has the effects of exciting beta receptors and anticholinergic receptors, expanding bronchus and relieving bronchospasm.
Herba ephedrae: pungent, slightly bitter and warm, entering lung and bladder meridians. The Chinese pharmacopoeia records that the hair has the functions of sweating, dispelling cold, ventilating and smoothing lung, relieving asthma, inducing diuresis and reducing edema. Can be used for treating common cold due to wind-cold, chest distress, cough, and edema; bronchial asthma.
Bitter apricot seeds: bitter and warm in nature, entering lung and large intestine meridians. Has effects of eliminating phlegm, relieving cough, relieving asthma and moistening intestine. It is indicated for cough due to exogenous pathogenic factor, dyspnea, throat impediment, constipation due to intestinal dryness. Not only can disperse and descend to regulate lung qi with ephedra, but also can disperse and descend to relieve asthma, and can coordinate with liquorice which is a decoction of stropanthus, thereby multiplying the efficacy of relieving cough and asthma.
Herba Ardisiae Japonicae: mild in nature, pungent and slightly bitter in flavor. It enters lung and liver meridians. Herba Ardisiae Japonicae has effects of eliminating phlegm, relieving cough, clearing away damp-heat, promoting blood circulation and removing blood stasis. It can be used for treating chronic cough, asthma and excessive phlegm. The formula of Danhe Fisher's Dan-Li Tang' is prepared from Angelica sinensis, and the Dan-Li Tang from Yi Chun-Yi (medical alcohol Reserve) is used for treating cough due to wind-phlegm entering lung. Prescription for convenience of grass and wood: it is indicated for chronic arthralgia due to wind-damp, lung rash and chronic cough. The modern pharmacology suggests that the Japanese ardisia herb has the effect of relieving cough, continuous administration has no tolerance and selectivity on the inhibition of cough centers.
Earthworm: bitter taste and cold nature, and has effects of clearing heat, arresting convulsion, dredging collaterals, relieving asthma, and promoting urination. The herba ephedrae is matched with herba ephedrae to have the functions of relaxing and relieving spasm of bronchial smooth muscle and relaxing capillary bronchus, so that the airway can be unobstructed, the respiratory resistance can be reduced, the ventilation and air exchange functions can be improved, and the mucous membrane can be repaired.
Dried orange peel: bitter, pungent and warm. It enters lung and spleen meridians. On one hand, the medicine has the efficacy of eliminating dampness and phlegm, and on the other hand, the medicine can prevent the stimulation of the medicines to the stomach.
And (3) inula flower rotation: also known as Jinboehuo herb, it is bitter, pungent, salty and slightly warm in flavor, entering lung, spleen, stomach and large intestine meridians. Has effects of lowering qi, eliminating phlegm, promoting diuresis, and relieving vomiting, and can be used for treating phlegm and saliva accumulation in lung, cough, asthma, excessive phlegm, phlegm and fluid accumulation, fullness in chest, belching and vomiting. Pungent flavor can disperse and move, lung qi can be dispersed and spread to the skin and hair, salty flavor can enter the kidney, and qi can be received and move downward to enter the root. "all flowers ascend and all descend" with revolving, covering flower has the functions of clearing lung qi, eliminating phlegm and removing retained fluid, and restoring lung qi and treating lung governing. Inula flower flavone has obvious protection effect on guinea pig bronchospasm asthma caused by histamine and also has resisting effect on guinea pig isolated bronchospasm caused by histamine, as described in Chinese materia medica.
Radix peucedani: dispel wind and clear heat, direct qi downward and resolve phlegm, and combined with Zi Wan for resolving phlegm and relieving cough. The compatibility of the two herbs is the property of the powder, so it is recorded in Yi Chun Yu Yi (medical alcohol Residul records) that it is used for treating lung meridian common cold, dizziness, headache, cough and profuse sputum.
Roasting radix asteris: bitter in taste, entering lung meridian, warm in nature without heat, moist without cold, and has certain curative effect on cough of new and old age.
Licorice root: has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and relieving cough, relieving spasm and pain, and harmonizing the drugs. Can be used together with dried orange peel as a guiding drug, and can be combined with ephedra herb and almond to form a stropanthus decoction, so that the cough relieving effect is obvious.
The invention uses the traditional Chinese medicine as the raw material, has no toxic or side effect, good taste and convenient administration, is prepared by repeated verification of clinical tests, and accords with the theory of the traditional Chinese medicine. The traditional Chinese medicine composition takes the lightyellow sophora root and the mix-fried ephedra herb as monarch drugs, and has the effects of dispelling wind, relieving spasm, relieving cough and asthma; bitter apricot seeds, Japanese ardisia herb, earthworm and dried orange peel are used as ministerial drugs to assist the monarch drugs to exert the effects of relieving spasm and asthma; inulae flos, radix Peucedani and radix Asteris preparata are used as adjuvant drugs to relieve cough and resolve phlegm; the liquorice is used as a guiding drug to coordinate the effects of the other drugs in the recipe.
When the medicines are used, the medicines which are equivalent to the weight ratio can be respectively cleaned, dried, crushed and mixed to obtain granules or powder with the granularity meeting the preparation requirement for direct administration. The medicines which are equivalent to the weight proportion relation can be used as raw materials, and after proper treatment, the medicines can be added with pharmaceutic adjuvant and made into various preparations according to the needs. In the process of preparing the preparation from the raw material medicines, the raw material medicines can be processed by adopting the following method: extracting with water or ethanol of different concentrations, respectively, concentrating the extractive solution, and drying to obtain crude extract; or further refining by one or more of alcohol precipitation, water dissolution, organic solvent extraction, flocculation precipitation, and column chromatography to obtain refined extract; the specific operation and/or use method for extracting the effective medicinal components can be a mode of respectively extracting the effective medicinal components of the medicinal components in the proportional amounts as raw materials and then mixing the effective medicinal components, or a mode of mixing the medicinal components in the proportional amounts and then extracting the medicinal components together. Different extraction methods, equipment and ideal or optimal extraction temperature, solvent dosage, extraction time, extraction times and other specific conditions required during extraction are adopted, and the extract can be screened and found through experiments according to actual conditions.
In order to make the raw materials of the drug exert better drug effects, the following preparation method is preferably adopted for the present invention:
the preparation method of the traditional Chinese medicine composition comprises the following steps:
weighing raw materials of radix Sophorae Flavescentis, herba Ephedrae preparata, semen Armeniacae amarum, herba Ardisiae Japonicae, Lumbricus, pericarpium Citri Tangerinae, Inulae flos, radix Peucedani, radix Asteris preparata, and Glycyrrhrizae radix, mixing, extracting with water or 50-95% ethanol, filtering, concentrating into soft extract, drying, and pulverizing into extract powder; adding or not adding auxiliary materials, and preparing into pharmaceutically acceptable preparations by conventional process.
The preparation method of the traditional Chinese medicine composition can also comprise the following steps:
weighing raw material medicines of radix sophorae flavescentis, mix-fried ephedra herb, bitter apricot seed, Japanese ardisia herb, earthworm, dried orange peel, inula flower, radix peucedani, mix-fried tatarian aster root and liquorice, adding 8-12 times of water for extracting for 1-3 times, each time for 0.5-2 hours, combining extracting solutions, filtering, concentrating into thick paste, drying, and crushing into paste powder; adding or not adding auxiliary materials, and preparing into pharmaceutically acceptable preparations by conventional process.
The prepared paste powder extract can be directly used as a medicine for administration or added with pharmaceutically acceptable auxiliary materials to prepare the required preparation by a conventional process. For example, the composition can be prepared into oral medicaments in solid preparation forms such as common tablets (dispersible tablets, effervescent tablets, orally disintegrating tablets, buccal tablets, chewable tablets and effervescent tablets), capsules (hard capsules and soft capsules), granules, pills (dropping pills, honey pills, water-honeyed pills and concentrated pills), powder, bagged tea and the like, and can also be prepared into oral medicaments in liquid preparation forms such as syrup, oral liquid and the like. Therefore, the pharmaceutical composition can also contain pharmaceutically acceptable auxiliary materials besides the extract of the traditional Chinese medicine composition.
The auxiliary materials described herein may be different depending on the formulation, such as diluents, disintegrants, excipients, binders, lubricants, surfactants, fillers, etc. which are commonly used in solid formulations such as tablets, capsules, granules, etc.; surfactants, diluents, preservatives, stabilizers, flavoring agents, thickeners, glidants and the like are commonly used in liquid preparation forms such as syrups, oral liquids and the like.
The common adjuvants include starch, lactose, dextrin, sugar powder, microcrystalline cellulose, mannitol, xylitol, polyethylene glycol, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, modified starch, sorbitol, polyvinylpyrrolidone, heavy magnesium carbonate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, ethyl cellulose, carboxymethyl starch sodium, hydroxypropyl cellulose, polyvidone K30, kaolin, pregelatinized starch, magnesium stearate, pulvis Talci, Gum Acacia, stevioside, betaine, aspartame, glycyrrhizin, saccharin sodium, citric acid, sorbic acid, potassium sorbate, ethylparaben, sucrose, starch syrup, guar gum, stevioside, sodium alginate, maltose, citric acid, malic acid, sucralose, menthol, coffee powder, monoglyceride, magnesium lauryl sulfate, betacyclodextrin, etc.
The preparation method of the granules of the traditional Chinese medicine composition comprises the following steps:
weighing raw material medicines of radix sophorae flavescentis, mix-fried ephedra herb, bitter apricot seed, Japanese ardisia herb, earthworm, dried orange peel, inula flower, radix peucedani, mix-fried tatarian aster root and liquorice, adding 8-12 times of water for extracting for 1-3 times, each time for 0.5-2 hours, combining extracting solutions, filtering, concentrating into thick paste, drying, and crushing into paste powder; adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
From the foregoing, it will be apparent that various other modifications, substitutions and variations can be made in the present invention without departing from the basic technical spirit of the invention, as defined by the common technical knowledge and common practice in the art.
Detailed Description
The present invention will be described in further detail with reference to the following examples. It should not be understood that the scope of the above-described subject matter of the present invention is limited to the following examples. All the technologies realized based on the above contents of the present invention belong to the scope of the present invention.
Example 1
Weighing 5g of radix sophorae flavescentis, 6g of roasted ephedra herb, 6g of bitter almond, 10g of Japanese ardisia herb, 10g of earthworm, 6g of dried orange peel, 6g of inula flower, 10g of radix peucedani, 10g of roasted aster and 5g of liquorice, mixing, adding 10 times of water for 2 times, extracting for 1 hour each time, combining extracting solutions, filtering, concentrating into thick paste, drying, crushing into paste powder, adding a proper amount of dextrin, soluble starch and aspartame, granulating, drying and finishing granules to obtain the granules.
Example 2
Weighing 2g of radix sophorae flavescentis, 8g of roasted ephedra herb, 2g of bitter almond, 20g of Japanese ardisia herb, 5g of earthworm, 10g of dried orange peel, 15g of inula flower, 3g of radix peucedani, 5g of roasted aster and 1g of liquorice, mixing, adding 12 times of water for 1 time, extracting for 2 hours, filtering, concentrating into thick paste, drying, crushing into paste powder, adding a proper amount of starch and powdered sugar, granulating, drying, finishing granules, adding magnesium stearate, mixing uniformly, tabletting, and coating or not coating to obtain the tablet.
Example 3
Weighing 15g of radix sophorae flavescentis, 10g of roasted ephedra herb, 1g of bitter almond, 15g of Japanese ardisia herb, 3g of earthworm, 2g of dried orange peel, 10g of inula flower, 20g of radix peucedani, 15g of roasted aster and 10g of liquorice, mixing, adding 11 times of water for 3 times, extracting for 0.5 hour each time, combining extracting solutions, filtering, concentrating into thick paste, drying, crushing into paste powder, adding a proper amount of auxiliary materials, granulating, drying, finishing granules and obtaining the granules.
Example 4
Weighing 10g of radix sophorae flavescentis, 2g of roasted ephedra herb, 15g of bitter almond, 5g of Japanese ardisia herb, 20g of earthworm, 1g of dried orange peel, 2g of inula flower, 15g of radix peucedani, 20g of roasted aster and 2g of liquorice, mixing, adding 8 times of 50% ethanol for extraction for 3 times, 0.5 hour each time, combining extracting solutions, filtering, recovering ethanol until no alcohol smell exists, concentrating to thick paste, drying, crushing to obtain paste powder, adding a proper amount of auxiliary materials, mixing uniformly, and preparing the powder.
Example 5
Weighing 1g of radix sophorae flavescentis, 15g of roasted ephedra herb, 10g of bitter almond, 3g of Japanese ardisia herb, 15g of earthworm, 8g of dried orange peel, 1g of inula flower, 5g of radix peucedani, 3g of roasted aster and 15g of liquorice, mixing, adding 12 times of 95% ethanol for extraction for 1 time for 2 hours, filtering, recovering ethanol until no ethanol smell exists, concentrating into thick paste, drying, crushing into paste powder, adding a proper amount of auxiliary materials, mixing uniformly, and preparing the pill.
Example 6
Weighing 12g of radix sophorae flavescentis, 9g of roasted ephedra herb, 8g of bitter almond, 10g of Japanese ardisia herb, 10g of earthworm, 15g of dried orange peel, 16g of inula flower, 10g of radix peucedani, 7g of roasted aster and 8g of liquorice, mixing, adding 70% ethanol in an amount which is 10 times that of the mixture, extracting for 2 times, 1 hour each time, combining extracting solutions, filtering, recovering ethanol until no alcohol smell exists, concentrating to thick paste, drying, crushing to obtain paste powder, adding a proper amount of dextrin and stevioside, granulating, drying and finishing granules to obtain the granules.
Example 7
Weighing 2g of radix sophorae flavescentis, 10g of roasted ephedra herb, 6g of bitter almond, 12g of Japanese ardisia herb, 15g of earthworm, 15g of dried orange peel, 2g of inula flower, 5g of radix peucedani, 10g of roasted aster and 12g of liquorice, mixing, adding 9 times of water for 2 times, extracting for 1 hour for the first time and 0.5 hour for the second time, combining extracting solutions, filtering, concentrating, adding ethanol until the alcohol concentration reaches 60%, standing for 36 hours, taking supernate, recovering ethanol until no alcohol taste exists, concentrating, adding a proper amount of water, uniformly stirring, refrigerating for 48 hours, filtering, adding a proper amount of suspension, flavoring agent and preservative into the filtrate, uniformly mixing, adding water for constant volume, filtering, and subpackaging to obtain the oral liquid preparation.
Example 8
Weighing 5g of radix sophorae flavescentis, 6g of roasted ephedra herb, 12g of bitter almond, 7g of Japanese ardisia herb, 12g of earthworm, 6g of dried orange peel, 6g of inula flower, 12g of radix peucedani, 12g of roasted aster and 5g of liquorice, mixing, adding 10 times of water for 2 times, extracting for 1 hour each time, combining extracting solutions, filtering, concentrating into thick paste, drying, crushing into paste powder, adding an appropriate amount of auxiliary materials, granulating, drying, finishing granules, and encapsulating to obtain the capsule.
The beneficial effects of the compositions according to the invention are further illustrated by the following test examples:
research on effect of traditional Chinese medicine composition for treating cough variant asthma
Action of relieving cough
20 mice with the weight of 19 +/-1 g are taken and randomly divided into two groups, wherein each group comprises 10 mice, and the male and female groups are respectively a model control group and a treatment group. The granules of example 1 according to the invention were administered to the treatment group in an amount corresponding to the clinically equivalent dose of 60Kg for adults. Each group of mice was administered by gavage 1 time a day with 0.2ml/10g body weight for 3 consecutive days, and the model control group was given distilled water under the same conditions. One hour after the last administration, the mice were placed in a plastic box of 30cm × 20cm × 15cm in order, ammonia was sprayed with an ultrasonic atomizer for 20 seconds, taken out and placed in a cage, the time from the taking out of the mice until the first cough occurred (latency) was recorded, and the number of coughs within 3 minutes was recorded, and the results were statistically processed using an inter-group test.
TABLE 1 antitussive effect of anti-allergic antitussive granules on mice
Group of | Animal number (only) | Incubation period (seconds) | Number of coughs (times) |
Model control group | 10 | 18.91±18.20 | 13.5±8.03 |
Treatment group | 10 | 27.70±3.63* | 7.6±4.07* |
As can be seen from Table 1, the treatment group has a certain effect of prolonging the latent period of mouse cough caused by ammonia water, has a certain effect of reducing the cough frequency of mice caused by ammonia water, and has significant difference (P is less than 0.05) compared with a model control group.
Second, asthma relieving action
30 guinea pigs with body weight of 225 + -25 g were divided into three groups, each group containing 10 male and female halves, and the three groups were blank control group, model control group, and treatment group. The granules of example 1 according to the invention were administered to the treatment group in an amount corresponding to the clinically equivalent dose of 60Kg for adults. Except for the blank control group, each of the other two groups of guinea pigs was intraperitoneally administered with 10% ovalbumin physiological saline 1ml, and the administration was started from the 3 rd day after the sensitization, 1 time daily, 1ml/100g body weight, and continued for 12 days, and the blank control group and the model control group were given distilled water under the same conditions. The weight was weighed once a week, and one hour after the last administration, guinea pigs were sequentially placed in a 30cm × 20cm × 15cm plastic box, sprayed with 5% ovalbumin physiological saline at constant pressure for 30 seconds using an ultrasonic atomizer, observed for 5 minutes after the spraying was stopped, and the time from when the guinea pigs stopped spraying until wheezy convulsions appeared (latency) and the number of animals that suffered a falling shock were recorded, and the results were statistically processed using an inter-group test.
TABLE 2 antitussive effects of anti-allergic antitussive granules on guinea pigs
As can be seen from Table 2, the treatment group has a certain effect of prolonging the latent period of the asthma of the guinea pig caused by the ovalbumin, has a certain effect of reducing the falling shock of the guinea pig caused by the ovalbumin, and has significant difference (P is less than 0.05) compared with a model control group.
Inventive examples 2-8 were similarly tested as described above, with the same results as described above.
Claims (10)
1. A traditional Chinese medicine composition for treating cough variant asthma is characterized by comprising the following raw material medicines in parts by weight: 1-15 parts of radix sophorae flavescentis, 1-15 parts of roasted ephedra herb, 1-15 parts of bitter almond, 3-20 parts of Japanese ardisia herb, 3-20 parts of earthworm, 1-15 parts of dried orange peel, 1-15 parts of inula flower, 3-20 parts of radix peucedani, 3-20 parts of roasted aster and 1-15 parts of liquorice.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw material medicines in parts by weight: 2-10 parts of radix sophorae flavescentis, 2-10 parts of fried ephedra herb, 2-10 parts of bitter almond, 5-15 parts of Japanese ardisia herb, 5-15 parts of earthworm, 2-10 parts of dried orange peel, 2-10 parts of inula flower, 5-15 parts of radix peucedani, 5-15 parts of fried aster and 2-10 parts of liquorice.
3. The traditional Chinese medicine composition according to claim 2, which is characterized by comprising the following raw material medicines in parts by weight: 5 parts of radix sophorae flavescentis, 6 parts of roasted ephedra herb, 6 parts of bitter almond, 10 parts of Japanese ardisia herb, 10 parts of earthworm, 6 parts of dried orange peel, 6 parts of inula flower, 10 parts of radix peucedani, 10 parts of roasted aster and 5 parts of liquorice.
4. A method for preparing the traditional Chinese medicine composition of any one of claims 1 to 3, which is characterized in that the method for preparing the composition comprises the following steps:
directly pulverizing the above raw materials to obtain medicinal powder; or extracting with water or ethanol of different concentrations, concentrating the extractive solution, and drying to obtain crude extract; or further refining by one or more of water extraction and ethanol precipitation, organic solvent extraction, column chromatography, and steam distillation to obtain refined extract; the crude extract or refined extract obtained from the powder of the medicinal materials is the active component of the traditional Chinese medicine composition, and the active component is prepared into any preparation in pharmaceutics according to the conventional process.
5. The method for preparing a Chinese medicinal composition according to claim 4, which is prepared by:
weighing raw materials of radix Sophorae Flavescentis, herba Ephedrae preparata, semen Armeniacae amarum, herba Ardisiae Japonicae, Lumbricus, pericarpium Citri Tangerinae, Inulae flos, radix Peucedani, radix Asteris preparata, and Glycyrrhrizae radix, mixing, extracting with water or 50-95% ethanol, filtering, concentrating into soft extract, drying, and pulverizing into extract powder; adding or not adding auxiliary materials, and preparing into pharmaceutically acceptable preparations by conventional process.
6. The method for preparing a Chinese medicinal composition according to claim 5, which is prepared by:
weighing raw material medicines of radix sophorae flavescentis, mix-fried ephedra herb, bitter apricot seed, Japanese ardisia herb, earthworm, dried orange peel, inula flower, radix peucedani, mix-fried tatarian aster root and liquorice, adding 8-12 times of water for extracting for 1-3 times, each time for 0.5-2 hours, combining extracting solutions, filtering, concentrating into thick paste, drying, and crushing into paste powder; adding or not adding auxiliary materials, and preparing into pharmaceutically acceptable preparations by conventional process.
7. The preparation method of the Chinese medicinal composition according to claim 5 or 6, wherein the preparation is tablets, granules, capsules, pills, powder or oral liquid.
8. The method for preparing a Chinese medicinal composition according to claim 7, wherein the preparation is in the form of granules.
9. The method for preparing a Chinese medicinal composition according to claim 8, wherein the granules are prepared by:
weighing raw material medicines of radix sophorae flavescentis, mix-fried ephedra herb, bitter apricot seed, Japanese ardisia herb, earthworm, dried orange peel, inula flower, radix peucedani, mix-fried tatarian aster root and liquorice, adding 8-12 times of water for extracting for 1-3 times, each time for 0.5-2 hours, combining extracting solutions, filtering, concentrating into thick paste, drying, and crushing into paste powder; adding appropriate amount of adjuvants, granulating, drying, and grading to obtain granule.
10. Use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for treating cough variant asthma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710350423.XA CN108938785B (en) | 2017-05-18 | 2017-05-18 | Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710350423.XA CN108938785B (en) | 2017-05-18 | 2017-05-18 | Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108938785A CN108938785A (en) | 2018-12-07 |
CN108938785B true CN108938785B (en) | 2022-06-10 |
Family
ID=64461796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710350423.XA Active CN108938785B (en) | 2017-05-18 | 2017-05-18 | Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108938785B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100404037C (en) * | 2006-01-19 | 2008-07-23 | 上海交通大学 | Chinese ephedra and earthworm composition for treating cough and gasp, and its preparation method |
-
2017
- 2017-05-18 CN CN201710350423.XA patent/CN108938785B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108938785A (en) | 2018-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010133015A1 (en) | Pharmaceutical composition for treating depression and preparative method and use thereof | |
CN107616501A (en) | A kind of composition with clearing lung-heat function and preparation method thereof | |
CN107617061A (en) | A kind of composition with clearing lung-heat moistening lung function and preparation method thereof | |
CN104887952B (en) | Composition with yin nourishing and lung moistening effects and preparation method and application thereof | |
CN110193061B (en) | Preparation and application of traditional Chinese medicine granules for treating or preventing children influenza virus infection | |
CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
CN101172145A (en) | Medicament for clearing heat, eliminating phlegm, relieving cough smoothing lung and preparation method thereof | |
CN103041151A (en) | Traditional Chinese medicine composition for curing trachitis and preparation method thereof | |
CN114288367B (en) | Traditional Chinese medicine composition for treating cough | |
CN103845633B (en) | It is a kind of to treat Chinese medicine composition of canker sore and preparation method thereof | |
CN108938785B (en) | Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof | |
CN104998162A (en) | Medicine for treating cough and preparing method of medicine | |
CN101647885B (en) | Medicine composition for treating coughs | |
CN103961455A (en) | Heat-clearing and detoxifying traditional Chinese medicine compound preparation and preparation method thereof | |
CN107753664B (en) | Traditional Chinese medicine composition for treating allergic rhinitis and preparation method thereof | |
CN101190282B (en) | Sugar-free compound traditional Chinese medicinal preparation for treating upper respiratory tract infection and quality control method thereof | |
CN106692496B (en) | Compound traditional Chinese medicine buccal tablet and preparation method and application thereof | |
CN111759901B (en) | Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof | |
CN104138441A (en) | Traditional Chinese medicine formula for treating infantile cough and asthma and preparation thereof | |
CN103055049A (en) | Buccal tablet for cough relieving and asthma relieving, and its preparation technology | |
CN101244170B (en) | Medicament for treating children's exogenous cough and preparation method | |
CN107596107B (en) | Heat-clearing, sore-throat-relieving and anti-allergic traditional Chinese medicine preparation and preparation method thereof | |
CN108721477B (en) | Pharmaceutical preparation for treating organ spasm and preparation method thereof | |
CN106177689A (en) | A kind of compositions with removing heat from the lung and dissipating phlegm antitussive effect and preparation method thereof | |
CN102048918A (en) | Traditional Chinese medicine preparation for treating bronchitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190116 Address after: No. 15, Saidabei Road, Xiqing Economic Development Zone, Tianjin 300385 Applicant after: Tianjin Ledun Traditional Chinese Medicine Co., Ltd. Address before: 102299 Beijing 6 Changping District science and Technology Park No. 79, No. 24, No. Applicant before: Beijing Kerui pharmaceutical Limited by Share Ltd profit innovation |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |